Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
Mahil, S. K., Bechman, K., Raharja, A., Domingo-Vila, C., Baudry, D., Brown, M. A., Cope, A. P., Dasandi, T., Graham, C., Khan, H., Lechmere, T., Malim, M. H., Meynell, F., Pollock, E., Sychowska, K., Barker, J. N., Norton, S., Galloway, J. B., Doores, K. J. & Tree, T. & 1 others, , Jan 2022, In: The Lancet Rheumatology. 4, 1, p. e42-e52
Research output: Contribution to journal › Article › peer-review